TerminatedPhase 2NCT02938793
Durvalumab in Combination With Tremelimumab in Subjects With Advanced Rare Solid Tumors
Studying Rare neoplastic disease
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Prisma Health-Upstate
- Principal Investigator
- William J Edenfield, MDPrisma Health-Upstate
- Intervention
- Durvalumab(drug)
- Enrollment
- 92 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2016 – 2025
Study locations (1)
- Greenville Health System Cancer Institute, Greenville, South Carolina, United States
Collaborators
AstraZeneca · MedImmune LLC
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT02938793 on ClinicalTrials.govOther trials for Rare neoplastic disease
Additional recruiting or active studies for the same condition.
- RECRUITINGNCT07147465Performance Indicators and Impact on the Care Pathway of Sequencing on the SeqOIA and AURAGEN (Seqogen) Platforms for Oncology PatientsAssistance Publique - Hôpitaux de Paris
- RECRUITINGPHASE2NCT04423185PLATFORM Study of Precision Medicine for Rare TumorsCancer Institute and Hospital, Chinese Academy of Medical Sciences